ArticleWorld journal of surgical oncology2026
FOXA2 promotes the occurrence and development of osteosarcoma cells by regulating ferroptosis through the Rheb/mTOR axis.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOsteosarcoma (OS) is a prevalent and aggressive primary carcinoma of the bone that predominantly influences children and adolescents. Inadequate therapeutic strategies have hindered improvements in patient survival. The forkhead box transcription factor FOXA2 plays a role in metabolic homeostasis and tumor progression. However, its association with OS remains underexplored.
methodsFirstly, we investigated the expression of FOXA2 in OS cells and in OS tissue samples from patients at different clinical stages using western blot and immunohistochemistry (IHC). Analysis of the R2 database revealed the association between FOXA2 and the prognosis of OS patients. Subsequently, a series of functional experiments confirmed the biological behaviors of OS caused by FOXA2. Furthermore, through western blot, chromatin immunoprecipitation (ChIP), dual-luciferase reporter assays, and other experiments, we identified a key underlying molecular mechanisms.
resultsThe present study determined that FOXA2 is overexpressed in OS cells and tissues, affecting OS patient prognosis. FOXA2 knockdownin functional experiments on OS cells attenuated their proliferation and migration while promoting ferroptosis, thereby offering an alternative intervention for OS as a form of programmed cell death. Upregulated Rheb restored the proliferation and migration in FOXA2 knockdown OS cells by facilitating ferroptosis induced by the mTOR pathway.
conclusionsThe study results corroborated that FOXA2 suppresses ferroptosis via the Rheb/mTOR axis, stimulating OS cell proliferation and migration. Targeting the FOXA2/Rheb/mTOR axis and clarifying the fundamental mechanisms are thus crucial for the clinical OS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.